-
Something wrong with this record ?
Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines
J. Simova, O. Sapega, T. Imrichova, I. Stepanek, L. Kyjacova, R. Mikyskova, M. Indrova, J. Bieblova, J. Bubenik, J. Bartek, Z. Hodny, M. Reinis,
Language English Country United States
Document type Journal Article
Grant support
NT14461
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Free Medical Journals
from 2010
Freely Accessible Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
- MeSH
- Bystander Effect drug effects MeSH
- Time Factors MeSH
- Cytokines genetics metabolism MeSH
- Neoplasms, Experimental genetics metabolism therapy MeSH
- Immunotherapy, Adoptive methods MeSH
- Interleukin-12 biosynthesis pharmacology MeSH
- Combined Modality Therapy MeSH
- Mice, Inbred C57BL MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents pharmacology MeSH
- Cellular Senescence drug effects MeSH
- Taxoids pharmacology MeSH
- Tumor Burden drug effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in the organism for protracted periods of time and they can promote tumor development. Based on this emerging concept, we hypothesized that elimination of such potentially cancer-promoting senescent cells could offer a therapeutic benefit. To assess this possibility, here we first show that tumor growth of proliferating mouse TC-1 HPV-16-associated cancer cells in syngeneic mice becomes accelerated by co-administration of TC-1 or TRAMP-C2 prostate cancer cells made senescent by pre-treatment with the anti-cancer drug docetaxel, or lethally irradiated. Phenotypic analyses of tumor-explanted cells indicated that the observed acceleration of tumor growth was attributable to a protumorigenic environment created by the co-injected senescent and proliferating cancer cells rather than to escape of the docetaxel-treated cells from senescence. Notably, accelerated tumor growth was effectively inhibited by cell immunotherapy using irradiated TC-1 cells engineered to produce interleukin IL-12. Collectively, our data document that immunotherapy, such as the IL-12 treatment, can provide an effective strategy for elimination of the detrimental effects caused by bystander senescent tumor cells in vivo.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18011106
- 003
- CZ-PrNML
- 005
- 20190703134939.0
- 007
- ta
- 008
- 180404s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.18632/oncotarget.10712 $2 doi
- 035 __
- $a (PubMed)27448982
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šímová, Jana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0119399
- 245 10
- $a Tumor growth accelerated by chemotherapy-induced senescent cells is suppressed by treatment with IL-12 producing cellular vaccines / $c J. Simova, O. Sapega, T. Imrichova, I. Stepanek, L. Kyjacova, R. Mikyskova, M. Indrova, J. Bieblova, J. Bubenik, J. Bartek, Z. Hodny, M. Reinis,
- 520 9_
- $a Standard-of-care chemo- or radio-therapy can induce, besides tumor cell death, also tumor cell senescence. While senescence is considered to be a principal barrier against tumorigenesis, senescent cells can survive in the organism for protracted periods of time and they can promote tumor development. Based on this emerging concept, we hypothesized that elimination of such potentially cancer-promoting senescent cells could offer a therapeutic benefit. To assess this possibility, here we first show that tumor growth of proliferating mouse TC-1 HPV-16-associated cancer cells in syngeneic mice becomes accelerated by co-administration of TC-1 or TRAMP-C2 prostate cancer cells made senescent by pre-treatment with the anti-cancer drug docetaxel, or lethally irradiated. Phenotypic analyses of tumor-explanted cells indicated that the observed acceleration of tumor growth was attributable to a protumorigenic environment created by the co-injected senescent and proliferating cancer cells rather than to escape of the docetaxel-treated cells from senescence. Notably, accelerated tumor growth was effectively inhibited by cell immunotherapy using irradiated TC-1 cells engineered to produce interleukin IL-12. Collectively, our data document that immunotherapy, such as the IL-12 treatment, can provide an effective strategy for elimination of the detrimental effects caused by bystander senescent tumor cells in vivo.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a bystander efekt $x účinky léků $7 D024201
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a stárnutí buněk $x účinky léků $7 D016922
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a cytokiny $x genetika $x metabolismus $7 D016207
- 650 _2
- $a imunoterapie adoptivní $x metody $7 D016219
- 650 _2
- $a interleukin-12 $x biosyntéza $x farmakologie $7 D018664
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a experimentální nádory $x genetika $x metabolismus $x terapie $7 D009374
- 650 _2
- $a taxoidy $x farmakologie $7 D043823
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a tumor burden $x účinky léků $7 D047368
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Sapega, Olena $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
- 700 1_
- $a Imrichová, Terezie $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. $7 _AN081460
- 700 1_
- $a Stepanek, Ivan $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
- 700 1_
- $a Kyjacova, Lenka $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic.
- 700 1_
- $a Mikyskova, Romana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic.
- 700 1_
- $a Indrová, Marie $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0069868
- 700 1_
- $a Bieblová, Jana $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0127729
- 700 1_
- $a Bubeník, Jan, $u First Faculty of Medicine, Charles University in Prague, Prague 12000, Czech Republic. $d 1940- $7 jk01020086
- 700 1_
- $a Bártek, Jiří, $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. Danish Cancer Society Research Center, Copenhagen DK-2100, Denmark. Department of Medical Biochemistry and Biophysics, Science For Life Laboratory, Division of Translational Medicine and Chemical Biology, Karolinska Institute, 17121 Solna, Sweden. $d 1953- $7 xx0046271
- 700 1_
- $a Hodný, Zdeněk $u Department of Genome Integrity, Institute of Molecular Genetics, v.v.i., Academy of Sciences of the Czech Republic, Prague 14220, Czech Republic. $7 xx0074117
- 700 1_
- $a Reiniš, Milan $u Immunology Unit, Czech Centre for Phenogenomics, BIOCEV and Department of Transgenic Models of Diseases, Institute of Molecular Genetics of the ASCR, v.v.i., Prague 14220, Czech Republic. $7 xx0083033
- 773 0_
- $w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 34 (2016), s. 54952-54964
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27448982 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20190703135129 $b ABA008
- 999 __
- $a ok $b bmc $g 1288591 $s 1007918
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 7 $c 34 $d 54952-54964 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
- GRA __
- $a NT14461 $p MZ0
- LZP __
- $a Pubmed-20180404